Arno Therapeutics IncOver The Counter Market:ARNI
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arno Therapeutics Inc | 2.9K | 0.0x | --- |
Poniard Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
GeneThera Inc | 40.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Refocus Group Inc | 20.0 | 0.0x | --- |
Company Information
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Contact Information
- Headquarters
- 200 Route 31 North, Suite 104FLEMINGTON, NJ, United States 08822
- Phone
- 862-703-7175
- Fax
- 908-237-0071
Executives
- Chairman of the Board
- Arie Belldegrun
- Chief Executive Officer, Chief Medical Officer, Vice President, Director
- Alexander Zukiwski
- Chief Development Officer
- Stefan Proniuk
- Secretary, Director
- David Tanen
- Director
- Jay Moorin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.43 |
Book Value | $-0.42 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
